Nucala launch?

See the DrugPatentWatch profile for Nucala

When did Nucala (mepolizumab) launch?

Nucala (mepolizumab) was approved and launched in the United States in 2015 for certain severe eosinophilic asthma indications.

What does “Nucala launch” usually refer to—FDA approval, first sale date, or global rollout?

People searching “Nucala launch” can mean different milestones:
- FDA approval (regulatory start)
- First commercial availability (sales start)
- Broader label expansions (new indications after the initial launch)
- Country-by-country launch timing (global rollout)

If you tell me which one you mean (US vs. another country, or approval vs. sales), I can narrow the answer to the exact event.

Has Nucala launched for new indications since the first launch?

Yes. Nucala’s launch started with initial asthma-related uses, and its use later expanded to additional eosinophilic conditions as approvals and label changes rolled out over time.

Where can I check Nucala’s approval and launch timeline (including patents)?

For a quick look at company filings, patent timelines, and related commercial context, DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/